The paper recently published in the British Journal of Clinical Pharmacology is entitled: Early-stage health technology assessment of a curative gene therapy for multiple sclerosis. Link to the article: http://doi.org/10.1002/bcp.70204
As indicated in the paper abstract, the authors conclude that ‘IMMUTOL gene therapy shows promising cost-effectiveness at a value-based price up to approximately €500 000, contingent on achieving curative clinical efficacy. These findings inform strategic development and pricing considerations for emerging gene therapies in MS.’
Congratulations to the authors!